Skip to main content

Table 1 Non-Malignant Disorders Treated With Cord Blood

From: Cord blood in regenerative medicine: do we need immune suppression?

Disorder Number Treated Outcome Ref.
Hurler's syndrome 20 17 of the 20 children were alive a median of 905 days after transplantation, with complete donor chimerism and normal peripheral-blood alpha-L-iduronidase activity [100]
Duchenne muscular dystrophy 1 On 42nd day, physical examination revealed obviously improvement in walking, turning the body over, and standing up [101]
Malignant infantile osteopetrosis 1 Normalization of spine bone mineral density. [102]
Rothmund-Thomson syndrome 1 Complete immune reconstitution [55]
Buerger's disease 4 Ischemic rest pain suddenly disappeared. Digital capillaries were increased in number and size. [84]
Spinal Cord Injury 1 Improved sensory perception and movement in the SPI patient's hips and thighs within 41 days of cell transplantation. Regeneration of the spinal cord at the injured site [85]
Krabbe's disease 25 Progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills in patient subset [14]
Omenn syndrome 1 T cell reconstitution [103]
Non-healing wounds 2 Accelerated healing [86]
Refractory anemia 3 All patients are alive and free of disease at between 17 and 39 months after cord blood administration [104]
Diamond-Blackfan anemia 1 Successful seroconversion to vaccines (diphtheria, pertussis, tetanus, rubella, measles, and BCG) administered 22–34 months post-transplant. [105]
Severe chronic active Epstein-Barr virus 1 Complete remission without circulating EBV-DNA has continued for 15 months transplant. [106]
Behcet's disease 1 Twenty-three months after CBT, the patient is doing well and has no signs or symptoms of Behcet's disease [9]
Mucopolysaccharidosis type IIB (Hunter syndrome) 1 Two years after transplant approximately 55% normal plasma iduronate sulfatase. activity has been restored and abnormal urinary excretion of glycosaminoglycans has nearly completely resolved. [107]